J&J/Basilea's Ceftobiprole Faces Another Setback
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A Nov. 26 FDA complete response letter to Johnson & Johnson and Basilea Pharmaceutica for their antibiotic ceftobiprole cites deficiencies of study conduct and requests further clinical site audits